# BIO-TECHNE Corp (TECH) financials

BIO-TECHNE Corp reported revenue of $1.22 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), down 0.4% from fiscal 2025. Net income was $182 million and diluted earnings per share $1.16.

In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $300 million, up 4.6% from a year earlier.

Source: BIO-TECHNE Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/TECH. Retrieved 2026-11-16.

## Latest results: Q1 FY2027

BIO-TECHNE Corp reported revenue of $300 million, up 4.6% from a year earlier, net income of $28.3 million and diluted earnings per share of $0.18 against $0.24 for the first quarter of fiscal 2027 (the three months to 30 Sep 2026).

From its quarterly report, filed 6 Nov 2026.

| Measure | Q1 FY2027 | Q1 FY2026 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $299.7M | $286.6M | +4.6% |
| Gross profit | $196.6M | $188.1M | +4.5% |
| Gross margin | 65.6% | 65.6% | −0.0 pts |
| Operating income | $36.60M | $47.66M | −23.2% |
| Operating margin | 12.2% | 16.6% | −4.4 pts |
| Net income | $28.29M | $38.18M | −25.9% |
| Diluted EPS | $0.18 | $0.24 | −25.0% |
| Operating cash flow | $73.11M | $27.59M | +165% |
| Capital expenditure | $5.92M | $5.36M | +10.3% |
| Free cash flow | $67.20M | $22.22M | +202% |

Page: https://aapwire.com/stocks/TECH/earnings

## Annual figures (fiscal years)

| Measure | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Revenue growth | +12.8% | +14.2% | +11.0% | +3.5% | +26.0% | +18.7% | +2.8% | +2.0% | +5.2% | −0.4% |
| Gross profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Operating income | $120.6M | $136.2M | $146.7M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Net income | $76.09M | $126.2M | $96.07M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.36M | $181.8M |
| Diluted EPS | $0.51 | $0.83 | $0.62 | $1.45 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Operating cash flow | $143.7M | $170.4M | $181.6M | $205.2M | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M | $292.1M |
| Capital expenditure | $15.18M | $20.93M | $25.41M | $51.74M | $44.30M | $44.91M | $38.24M | $62.88M | $31.01M | $28.85M |
| Free cash flow | $128.5M | $149.4M | $156.2M | $153.5M | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
| Gross margin | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating margin | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net margin | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| Cash and equivalents | $91.61M | $122.0M | $100.9M | $146.6M | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Total debt | $343.8M | $339.0M | $505.2M | $433.5M | $420.6M | $326.0M | $455.0M | $419.5M | $444.1M | $289.1M |
| Shareholders' equity | $949.6M | $1.08B | $1.17B | $1.38B | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
| Diluted shares | 150M | 152M | 156M | 158M | 162M | 164M | 162M | 161M | 160M | 157M |
| Dividends per share | $0.32 | $0.32 | $0.32 | $0.32 | $0.32 | $0.80 | $0.32 | $0.32 | $0.32 | $0.32 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $297.0M | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M | $321.2M | $299.7M |
| Revenue, year on year | +9.0% | +4.2% | +3.5% | −1.0% | −0.4% | −1.5% | +1.3% | +4.6% |
| Gross margin | 65.3% | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% | 65.8% | 65.6% |
| Operating income | $47.42M | $38.71M | −$23.86M | $47.66M | $54.46M | $75.50M | $74.28M | $36.60M |
| Net income | $34.89M | $22.59M | −$17.70M | $38.18M | $38.00M | $51.04M | $54.64M | $28.29M |
| Diluted EPS | $0.22 | $0.14 | −$0.11 | $0.24 | $0.24 | $0.32 | $0.35 | $0.18 |
| Free cash flow | $77.53M | $31.00M | $93.31M | $22.22M | $76.49M | $77.58M | $86.94M | $67.20M |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Product and Services revenue](https://aapwire.com/stocks/TECH/kpi/product-and-services-revenue) | $285.2M | quarter to 30 Sep 2026 | up 1.5% |
| [Consumables revenue](https://aapwire.com/stocks/TECH/kpi/consumables-revenue) | $237.3M | quarter to 30 Sep 2026 | up 2.4% |
| [Instruments revenue](https://aapwire.com/stocks/TECH/kpi/instruments-revenue) | $25.5M | quarter to 30 Sep 2026 | up 16.8% |
| [Services revenue](https://aapwire.com/stocks/TECH/kpi/services-revenue) | $22.5M | quarter to 30 Sep 2026 | down 18.3% |
| [Royalty revenue](https://aapwire.com/stocks/TECH/kpi/royalty-revenue) | $14.5M | quarter to 30 Sep 2026 | up 156.7% |
| [Protein Sciences revenue](https://aapwire.com/stocks/TECH/kpi/protein-sciences-revenue) | $219.7M | quarter to 30 Sep 2026 | up 8.7% |
| [Diagnostics and Spatial Biology revenue](https://aapwire.com/stocks/TECH/kpi/diagnostics-and-spatial-biology-revenue) | $80.2M | quarter to 30 Sep 2026 | up 0.9% |
| [United States revenue](https://aapwire.com/stocks/TECH/kpi/united-states-revenue) | $152.7M | quarter to 30 Sep 2026 | down 1.7% |
| [EMEA, excluding United Kingdom revenue](https://aapwire.com/stocks/TECH/kpi/emea-excluding-united-kingdom-revenue) | $73.9M | quarter to 30 Sep 2026 | up 13.5% |
| [China revenue](https://aapwire.com/stocks/TECH/kpi/china-revenue) | $28.9M | quarter to 30 Sep 2026 | up 16.6% |
| [APAC, excluding Greater China revenue](https://aapwire.com/stocks/TECH/kpi/apac-excluding-greater-china-revenue) | $22.5M | quarter to 30 Sep 2026 | up 17.3% |
| [United Kingdom revenue](https://aapwire.com/stocks/TECH/kpi/united-kingdom-revenue) | $13.7M | quarter to 30 Sep 2026 | up 4.0% |
| [Rest of World revenue](https://aapwire.com/stocks/TECH/kpi/rest-of-world-revenue) | $8.1M | quarter to 30 Sep 2026 | down 11.0% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
